These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 34884211

  • 1. Predictors of Tumour Growth and Autonomous Cortisol Secretion Development during Follow-Up in Non-Functioning Adrenal Incidentalomas.
    Araujo-Castro M, Parra Ramírez P, Robles Lázaro C, García Centeno R, Gracia Gimeno P, Fernández-Ladreda MT, Sampedro Núñez MA, Marazuela M, Escobar-Morreale HF, Valderrabano P.
    J Clin Med; 2021 Nov 25; 10(23):. PubMed ID: 34884211
    [Abstract] [Full Text] [Related]

  • 2. Predictive model for autonomous cortisol secretion development in non-functioning adrenal incidentalomas.
    Araujo-Castro M, García Cano AM, Escobar-Morreale HF, Valderrabano P.
    Hormones (Athens); 2023 Mar 25; 22(1):51-59. PubMed ID: 36279032
    [Abstract] [Full Text] [Related]

  • 3. Nonfunctioning adrenal incidentalomas with cortisol post-dexamethasone suppression test >0.9 µg/dL have a higher prevalence of cardiovascular disease than those with values ≤0.9 µg/dL.
    Araujo-Castro M, Parra Ramírez P, Martín Rojas-Marcos P, García Centeno R, Gracia Gimeno P, Tomé Fernández-Ladreda M, Sampedro Núñez MA, Higueruela C, Robles Lázaro C.
    Endocrine; 2023 Feb 25; 79(2):384-391. PubMed ID: 36261701
    [Abstract] [Full Text] [Related]

  • 4. Is the 1mg-dexamethasone suppression test a precise marker of glucocorticoid excess and cardiometabolic risk in patients with adrenal incidentalomas?
    Araujo-Castro M, Hanzu FA, Pascual-Corrales E, García Cano AM, Marchan M, Escobar-Morreale HF, Valderrabano P, Casals G.
    Endocrine; 2023 Oct 25; 82(1):161-170. PubMed ID: 37351760
    [Abstract] [Full Text] [Related]

  • 5. Maximum adenoma diameter, regardless of uni- or bilaterality, is a risk factor for autonomous cortisol secretion in adrenal incidentalomas.
    Araujo-Castro M, Robles Lázaro C, Parra Ramírez P, García Centeno R, Gracia Gimeno P, Fernández-Ladreda MT, Sampedro Núñez MA, Marazuela M, Escobar-Morreale HF, Valderrabano P.
    J Endocrinol Invest; 2021 Nov 25; 44(11):2349-2357. PubMed ID: 33683661
    [Abstract] [Full Text] [Related]

  • 6. Cardiometabolic profile of non-functioning and autonomous cortisol-secreting adrenal incidentalomas. Is the cardiometabolic risk similar or are there differences?
    Araujo-Castro M, Robles Lázaro C, Parra Ramírez P, Cuesta Hernández M, Sampedro Núñez MA, Marazuela M.
    Endocrine; 2019 Dec 25; 66(3):650-659. PubMed ID: 31473918
    [Abstract] [Full Text] [Related]

  • 7. Clinical features, risk of mass enlargement, and development of endocrine hyperfunction in patients with adrenal incidentalomas: a long-term follow-up study.
    Falcetta P, Orsolini F, Benelli E, Agretti P, Vitti P, Di Cosmo C, Tonacchera M.
    Endocrine; 2021 Jan 25; 71(1):178-188. PubMed ID: 32915435
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Characterisation of the urinary steroid profile of patients with nonfunctioning adrenal incidentalomas: A matched controlled cross-sectional study.
    Araujo-Castro M, Casals G, Hanzu FA, Pascual-Corrales E, García Cano AM, Lanza VF, Luis Del Rey Mejías Á, Marchan M, Escobar-Morreale HF, Valderrabano P.
    Clin Endocrinol (Oxf); 2023 Feb 25; 98(2):165-176. PubMed ID: 35973974
    [Abstract] [Full Text] [Related]

  • 10. Accuracy of the dexamethasone suppression test for the prediction of autonomous cortisol secretion-related comorbidities in adrenal incidentalomas.
    Araujo-Castro M, Parra Ramírez P, Robles Lázaro C, García Centeno R, Gracia Gimeno P, Fernández-Ladreda MT, Sampedro Núñez MA, Marazuela M, Escobar-Morreale HF, Valderrabano P.
    Hormones (Athens); 2021 Dec 25; 20(4):735-744. PubMed ID: 34273083
    [Abstract] [Full Text] [Related]

  • 11. Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study.
    Deutschbein T, Reimondo G, Di Dalmazi G, Bancos I, Patrova J, Vassiliadi DA, Nekić AB, Debono M, Lardo P, Ceccato F, Petramala L, Prete A, Chiodini I, Ivović M, Pazaitou-Panayiotou K, Alexandraki KI, Hanzu FA, Loli P, Yener S, Langton K, Spyroglou A, Kocjan T, Zacharieva S, Valdés N, Ambroziak U, Suzuki M, Detomas M, Puglisi S, Tucci L, Delivanis DA, Margaritopoulos D, Dusek T, Maggio R, Scaroni C, Concistrè A, Ronchi CL, Altieri B, Mosconi C, Diamantopoulos A, Iñiguez-Ariza NM, Vicennati V, Pia A, Kroiss M, Kaltsas G, Chrisoulidou A, Marina LV, Morelli V, Arlt W, Letizia C, Boscaro M, Stigliano A, Kastelan D, Tsagarakis S, Athimulam S, Pagotto U, Maeder U, Falhammar H, Newell-Price J, Terzolo M, Fassnacht M.
    Lancet Diabetes Endocrinol; 2022 Jul 25; 10(7):499-508. PubMed ID: 35533704
    [Abstract] [Full Text] [Related]

  • 12. Diabetes Mellitus in Non-Functioning Adrenal Incidentalomas: Analysis of the Mild Autonomous Cortisol Secretion (MACS) Impact on Glucose Profile.
    Trandafir AI, Ghemigian A, Ciobica ML, Nistor C, Gurzun MM, Nistor TVI, Petrova E, Carsote M.
    Biomedicines; 2024 Jul 18; 12(7):. PubMed ID: 39062179
    [Abstract] [Full Text] [Related]

  • 13. Increased mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: a 13-year retrospective study from one center.
    Patrova J, Kjellman M, Wahrenberg H, Falhammar H.
    Endocrine; 2017 Nov 18; 58(2):267-275. PubMed ID: 28887710
    [Abstract] [Full Text] [Related]

  • 14. Diagnostic testing of autonomous cortisol secretion in adrenal incidentalomas.
    Ueland GÅ, Grinde T, Methlie P, Kelp O, Løvås K, Husebye ES.
    Endocr Connect; 2020 Oct 18; 9(10):963-970. PubMed ID: 33032259
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pros and cons of dexamethasone suppression test for screening of subclinical Cushing's syndrome in patients with adrenal incidentalomas.
    Reimondo G, Allasino B, Bovio S, Saba L, Ardito A, Angeli A, Terzolo M.
    J Endocrinol Invest; 2011 Jan 18; 34(1):e1-5. PubMed ID: 20634637
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of Body Composition in Patients With and Without Adrenal Tumors and Without Overt Hypersecretory Syndromes.
    Araujo-Castro M, Pascual-Corrales E, García Cano AM, Marchan M, Casals G, Hanzu FA, Gomez-Bermejo MÁ, Escobar Morreale HF, Valderrabano P.
    Endocr Pract; 2023 Feb 18; 29(2):110-118. PubMed ID: 36455692
    [Abstract] [Full Text] [Related]

  • 18. The Steroid Profile of Adrenal Incidentalomas: Subtyping Subjects With High Cardiovascular Risk.
    Di Dalmazi G, Fanelli F, Zavatta G, Ricci Bitti S, Mezzullo M, Repaci A, Pelusi C, Gambineri A, Altieri P, Mosconi C, Balacchi C, Golfieri R, Cosentino ER, Borghi C, Vicennati V, Pasquali R, Pagotto U.
    J Clin Endocrinol Metab; 2019 Nov 01; 104(11):5519-5528. PubMed ID: 31381072
    [Abstract] [Full Text] [Related]

  • 19. The low-dose dexamethasone suppression test in patients with adrenal incidentalomas: comparisons with clinically euadrenal subjects and patients with Cushing's syndrome.
    Tsagarakis S, Kokkoris P, Roboti C, Malagari C, Kaskarelis J, Vlassopoulou V, Alevizaki C, Thalassinos N.
    Clin Endocrinol (Oxf); 1998 May 01; 48(5):627-33. PubMed ID: 9666875
    [Abstract] [Full Text] [Related]

  • 20. Autonomous cortisol secretion in adrenal incidentalomas and increased visceral fat accumulation during follow-up.
    Yener S, Baris M, Peker A, Demir O, Ozgen B, Secil M.
    Clin Endocrinol (Oxf); 2017 Nov 01; 87(5):425-432. PubMed ID: 28656620
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.